Abstract

Prostate cancer (PCa) is the second most frequently diagnosed cancer among men worldwide, with almost 1.3 million new cases and 360,000 deaths in 2018. As it has been estimated, its mortality will double by 2040, mostly in countries with limited resources. These numbers suggest that recent trends in deep learning-based computer-aided diagnosis could play an important role, serving as screening methods for PCa detection. These algorithms have already been used with histopathological images in many works, in which authors tend to focus on achieving high accuracy results for classifying between malignant and normal cases. These results are commonly obtained by training very deep and complex convolutional neural networks, which require high computing power and resources not only in this process, but also in the inference step. As the number of cases rises in regions with limited resources, reducing prediction time becomes more important. In this work, we measured the performance of current state-of-the-art models for PCa detection with a novel benchmark and compared the results with PROMETEO, a custom architecture that we proposed. The results of the comprehensive comparison show that using dedicated models for specific applications could be of great importance in the future.

Highlights

  • Prostate cancer (PCa) is the second most common cancer and the fifth leading cause of cancer death in men (GLOBOCAN [1])

  • The network achieved 99.98% accuracy, 99.98% F1 score and 0.999 areas under the curve (AUC) on a separate test set at patch level after training the network with a 3-fold cross-validation method

  • The first one is the custom convolutional neural networks (CNNs) model, called PROMETEO, which we proposed in [15], where we demonstrated that applying stain-normalization algorithms to the patches in order to reduce color variability could improve the generalization of the model when predicting new unseen images from different hospitals and scanners

Read more

Summary

Introduction

Prostate cancer (PCa) is the second most common cancer and the fifth leading cause of cancer death in men (GLOBOCAN [1]). According to the World Health Organization (WHO), there will be an increase of prostate cancer (PCa) cases worldwide, with 1,017,712 new cases being estimated for 2040 Most of these cases will be registered in Africa, Latin America, the Caribbean and Asia, and appear to be related to an increased life expectancy [2]. In the case of abnormal DRE and elevated PSA results, trans-rectal ultrasound-guided biopsy is performed to obtain samples of the prostate tissue [3]. These tissue samples are scanned, resulting on gigapixel-resolution images called whole-slide images (WSIs), which are analyzed and diagnosed by pathologists

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call